TAKEDA PHARMACEUTICALS AMERICA, INC. for TAKEDA PHARMACEUTICALS AMERICA INC
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Importation issues; Preserve Access to Affordable Generics Act; S. 319 Pharmaceutical Market Access and Drug Safety Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Copyright/Patent/Trademark CPT
S. 23 Patent Reform Act of 2011; S. 27 Preserve Access to Affordable Generics; general patent settlement issues; HR 1249, America Invents Act; S. 968, the PROTECT IP Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Medical/Disease Research/Clinical Labs MED
Regenerative Medicines Promotion Act; Gastrointestinal and Motility Disorders Research Enhancement Act (H.R. 2239)
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Manufacturing MAN
Prescription Drug User Fee Act Reauthorization; FDA Sentinel Pilot; S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R.2245, Preserving Access to Life-Saving Medications Act of 2011; DTC advertising; HR 1483 Drug Import Ssafety legislation;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Taxation/Internal Revenue Code TAX
Implementaton of ACA Pharmaceutical fee; corporate tax reform, R&D tax credit extension; Debt commissions recommendations; Reid/Baucus Lundgren repeal of Patient Protection and Affordable Care Act; Innovate America Act; Ryan Roadmap; Debt and deficit negotiations; foreign tax reforms; HR. 2190/S.1206 Medicare Drug Savings Act of 2011
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Health Issues HCR
General comparative effectiveness issues, health reform and the un/underinsured, chronic disease legislation (diabetes, mental health, obesity, CKD), value based insurance design, quality of care, adhereance, ACA implementation; Anit-Gout USP matters; PCORI; Essential benefits package, ESRD bundling implementation; coverage gap, S. 371/HR741 Bill to prohibit authorized generics, Debt and Deficit negotiations HR 2, Repealing the Job-Killing Health Care Law ; Office of Consumer Information and Insurance Oversight; Essential Benefits Committee; Comparative Effectiveness; Patient Centered Outcomes Research Institute; S. 668 The Health Care Bureaucrats Elimination Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURA ELIZABETH CLINE | — |
| DEBORAH LYNN WALTER | — |
| ANDREA WILKINSON | — |
Medicare/Medicaid MMM
340B-1 and AMP, Part D coverage gap discount program implelmentation, Protected Classes, Comparative Effectiveness, general Medicare/Medicaid expansions and reform; Value based Purchasing Program; End Stage Renal Disease final rules; TRICARE, HR 457 Medicare Decisions Accountability Act of 2011 (IPAB repeal), Medicare Evident Development and Coverage Ad Com.; Medicare Payment Advisory Commission; S. 31 Prescription Drug and Health Improvement Act; Debt and deficit negotiations S. 44 Medicare Prescription Drug Price Negotiation Act; CMS proposed Medicare Advantage; S 373 Fair Prescription Drug Competition Act; Ryan Roadmap; HR. 2190/S.1206 Medicare Drug Savings Act of 2011; the Medicaid Improvement and State Empowerment Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| LAURA ELIZABETH CLINE | — |
| DEBORAH LYNN WALTER | — |
| ANDREA WILKINSON | — |
Budget/Appropriations BUD
Agriculture; Labor, HHS; Commerce and Homeland Security Departments Appropriation Bills
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANDREA WILKINSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.